Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RY6 | Q15077 | 8/20 | 0.59 |
| ▸ | P2RY2 | P41231 | 11/20 | 0.58 |
| ▸ | P2RY4 | P51582 | 7/20 | 0.58 |
| ▸ | P2RY14 | Q15391 | 6/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18126746 | 1.00 | P2RY6 (0.59) | P2RY6P2RY2P2RY4P2RY14 | |
| SCHEMBL19546708 | 1.00 | P2RY6 (0.59) | P2RY6P2RY2P2RY4P2RY14 | |
| SCHEMBL24043084 | 1.00 | P2RY6 (0.59) | P2RY6P2RY2P2RY4P2RY14 | |
| SCHEMBL21763394 | 0.94 | P2RY6 (0.56) | P2RY6P2RY2P2RY4P2RY14 | |
| SCHEMBL20327073 | 0.93 | P2RY6 (0.54) | P2RY6P2RY2P2RY4P2RY14 | |
| SCHEMBL17577464 | 0.93 | P2RY2 (0.56) | P2RY6P2RY2P2RY4P2RY14 | |
| SCHEMBL15989014 | 0.93 | P2RY2 (0.56) | P2RY6P2RY2P2RY4P2RY14 | |
| SCHEMBL20669163 | 0.93 | P2RY6 (0.54) | P2RY6P2RY2P2RY4P2RY14 | |
| SCHEMBL25955354 | 0.92 | P2RY2 (0.60) | P2RY6P2RY2P2RY4P2RY14 | |
| SCHEMBL22899110 | 0.92 | P2RY6 (0.53) | P2RY6P2RY2P2RY4P2RY14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023173061-A2 | OLIGONUCLEOTIDES FOR APP MODULATION | UNIVERSITY OF MASSACHUSETTS (US) | 2023-09-14 | — | — | WO | disclosed |
| US-11753638-B2 | Conjugated oligonucleotides | UNIVERSITY OF MASSACHUSETTS (US) | 2023-09-12 | — | — | US | disclosed |
| WO-2023114989-A2 | OLIGONUCLEOTIDES FOR MLH3 MODULATION | UNIVERSITY OF MASSACHUSETTS (US) | 2023-06-22 | — | — | WO | disclosed |
| US-20220010309-A1 | SYNTHESIS OF MODIFIED OLIGONUCLEOTIDES WITH INCREASED STABILITY | UNIVERSITY OF MASSACHUSETTS | 2022-01-13 | — | — | US | disclosed |
| EP-3929293-A2 | FULLY STABILIZED ASYMMETRIC SIRNA | University Of Massachusetts (US) | 2021-12-29 | — | — | EP | disclosed |
| US-20210363524-A1 | OLIGONUCLEOTIDES FOR SNCA MODULATION | UNIVERSITY OF MASSACHUSETTS | 2021-11-25 | — | — | US | disclosed |
| EP-3766973-A1 | OLIGONUCLEOTIDE COMPOUNDS FOR TARGETING HUNTINGTIN MRNA | University Of Massachusetts (US) | 2021-01-20 | — | — | EP | disclosed |
| EP-3277814-B1 | OLIGONUCLEOTIDE COMPOUNDS FOR TARGETING HUNTINGTIN MRNA | UNIV MASSACHUSETTS (US) | 2020-06-03 | — | — | EP | disclosed |
| WO-2018031933-A2 | CONJUGATED OLIGONUCLEOTIDES | UNIVERSITY OF MASSACHUSETTS (US) | 2018-02-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11753638-B2 | Conjugated oligonucleotides | DCLRE1B, DCLRE1A, TNNC1 | P2RY6 4536/4885P2RY2 4693/4885P2RY4 4709/4885 |
| US-20210363524-A1 | OLIGONUCLEOTIDES FOR SNCA MODULATION | SNCA, PARK7, SMN1; SMN2 | P2RY6 3331/4885P2RY2 3083/4885P2RY4 2950/4885 |
| US-20220010309-A1 | SYNTHESIS OF MODIFIED OLIGONUCLEOTIDES WITH INCREASED STABILITY | NSUN2, RNGTT, RNMT | P2RY6 2868/4885P2RY2 3745/4885P2RY4 3293/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.